Carvedilol Tablet, Film Coated
Product Images NDC 68071-2780

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 68071-2780). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2780 8)

This is a drug packaging label for Carvedilol 6.25 mg tablets, film coated, oral use, distributed by NuCare Pharmaceuticals, Inc. The label specifies a package containing 180 tablets. The tablets are described as round, biconvex, beveled edge, white to off-white, debossed with 'ZC40' on one side. The label includes NDC 68071-2780-8 and states the product is prescription-only with storage instructions at controlled temperature (68-77°F). Manufacturer information notes Cadila Healthcare Ltd, India.*

FDA Label Image

Structured Formula For Carvedilol (B1fa8af3 9789 45d2 8b77 A53935c52b49 01)

Chemical structure of Carvedilol, showing multiple aromatic rings and functional groups including hydroxyl and methoxy substituents, corresponding to the active ingredient Carvedilol.*

FDA Label Image

Carvedilol Tablets (B1fa8af3 9789 45d2 8b77 A53935c52b49 02)

A line graph comparing % mortality over 21 months between placebo and Carvedilol groups. The vertical axis shows % mortality (0-30%), and the horizontal axis shows time in months (0-21). Two lines indicate mortality trends, with Carvedilol showing consistently lower mortality than placebo. A p-value of 0.0014 is noted on the graph.*

FDA Label Image

Carvedilol Tablets (B1fa8af3 9789 45d2 8b77 A53935c52b49 03)

A forest plot chart depicting hazard ratios and confidence intervals across multiple patient groups. The groups analyzed include gender, age categories, race, diabetic status, ischemic condition, heart rate, systolic blood pressure, and spironolactone use. The x-axis shows the hazard ratio scale from 0.0 to 2.0 with a reference line at 1.0, illustrating risk comparisons for each subgroup.*

FDA Label Image

Structured Formula For Carvedilol (B1fa8af3 9789 45d2 8b77 A53935c52b49 04)

A line graph showing the percentage of mortality over 24 months comparing Carvedilol and Placebo. The x-axis represents months, and the y-axis represents mortality percentage from 0% to 30%. Carvedilol shows a lower mortality rate compared to Placebo throughout the period, with a p-value of 0.03 indicating statistical significance.*

FDA Label Image

Structured Formula For Carvedilol (B1fa8af3 9789 45d2 8b77 A53935c52b49 05)

A forest plot illustrating hazard ratios for various subgroups including age, sex, timing post-myocardial infarction, prior use of beta-blockers, Killip class, thrombolytic use, PTCA use, congestive heart failure status, angina presence, hypertension status, diabetes status, heart rate, systolic blood pressure, and all patients overall. The hazard ratios are depicted with horizontal lines and central dots, comparing each subgroup's outcomes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.